Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kala Pharmaceuticals ( (KALA) ) has provided an update.
On July 9, 2025, KALA BIO, Inc. announced the completion of patient enrollment for the CHASE Phase 2b clinical trial, which evaluates KPI-012 for treating persistent corneal epithelial defect (PCED). This trial, involving 79 patients across the U.S. and Latin America, aims to assess the safety and efficacy of KPI-012. The company anticipates reporting topline data in the third quarter of 2025, and positive results could lead to a pivotal trial supporting a Biologics License Application to the FDA.
The most recent analyst rating on (KALA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Kala Pharmaceuticals stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.
To see Spark’s full report on KALA stock, click here.
More about Kala Pharmaceuticals
Kala Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development of therapies for eye diseases. The company specializes in innovative treatments, particularly using human mesenchymal stem cell secretome for ocular conditions.
Average Trading Volume: 70,552
Technical Sentiment Signal: Sell
Current Market Cap: $34.07M
Find detailed analytics on KALA stock on TipRanks’ Stock Analysis page.